Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): Role of muscarinic receptors;Regulación del tono bronquial en la enfermedad pulmonar obstructiva crónica (EPOC): Papel de los receptores muscarínicos

Anales de Medicina Interna

Volumn 20, Issue 4, 2003, Pages 201-205

  Abad Santos, Francisco ^a   Novalbos, J ^a   Gallego Sandin S ^a   Galvez Mugica M A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

COPD; Ipratropium; Muscarinic receptors; Tiotropium

Indexed keywords

ACETYLCHOLINE; AUTORECEPTOR; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR; RECEPTOR SUBTYPE; TIOTROPIUM BROMIDE;

ACETYLCHOLINE RELEASE; BINDING AFFINITY; BRONCHODILATATION; BRONCHOSPASM; BRONCHUS MUSCLE; BRONCHUS TONE; CHOLINERGIC TRANSMISSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; MUCUS SECRETION; PARASYMPATHETIC GANGLION; RECEPTOR BINDING; REVIEW; TREATMENT PLANNING;

BRONCHI; BRONCHODILATOR AGENTS; HUMANS; IPRATROPIUM; MUSCARINIC ANTAGONISTS; MUSCLE, SMOOTH; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC; SCOPOLAMINE DERIVATIVES;

EID: 0038219809     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Barnes PJ, Belvisi MG, Mak JC, Haddad EB, O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995; 56: 853-9.
2. White MV. Muscarinic receptors in human airways. J Allergy Clin Immunol 1995; 95: 1065-8.
3. Hurlé MA. Fármacos antiasmáticos y broncodilatadores. En: Flórez J, Armijo JA, Mediavilla A, dir. Farmacología humana, 3a ed. Barcelona: Masson, 1997; 705-21.
4. Mark JCW, Barnes PJ. Autoradiographic visualization of muscarinic receptors subtypes in human and guinea pig lung. Am Rev Respir Dis 1990; 141: 1559-68.
5. Rang HP, Dale MM. Sistema respiratorio. En: Rang HP, Dale MM. Farmacología. Madrid: Alhambra Longman, 1992; 430-50.
6. Campbell SC. Clinical aspects of inhaled anticholinergic therapy. Respir Care 2000; 45: 864-7.
7. Emala CW, Aryana A, Levine MA, Yasuda RP, Satkus SA, Wolfe BB, et al. Expression of muscarinic receptor subtypes and M2-muscarinic inhibition of adenylyl cyclase in lung. Am J Physiol 1995; 268: L101-7.
8. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117 (Supl. 2): 10S-14S.
9. Pistelli R, Patalano F, Liberatore SM, Incalzi RA, Ciappi G. Selectivity of anticholinergic drugs on central and peripheral airways in normal subjects. Eur J Respir Dis 1983; 128 (Supl.): 499-502.
10. Calverley PM. The future for tiotropium. Chest 2000; 117 (Supl. 2): 67S-69S.
11. Haddad EB, Mak JC, Belvisi MG, Nishikawa M, Rousell J, Barnes PJ. Muscarinic and β-adrenergic receptor expression in peripheral lung from normal and asthmatic patients. Am J Physiol 1996; 270: L947-53.
12. Brown JH, Taylor P. Muscarinic receptors agonists and antagonists. En: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacologic Basis of Therapeutics, 10a edición. Nueva York: McGraw-Hill, 2001: 155-73.
13. Tashkin DP, Ashutosh K, Bleecker ER, Britt EJ, Cugell DW, Cummiskey JM, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med 1986; 81 (5A): 81-90.
14. Disse B. Antimuscarinic treatment for lung diseases: from research to clinical practice. Life Sci 2001; 68: 2557-64.
15. Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998; 274: L970-9.
16. Ghafouri MA, Patil KD, Kass I. Sputum changes associated with the use of ipratropium bromide. Chest 1984; 86: 387-93.
17. Taylor RG, Pavia D, Agnew JE, Lopez-Vidriero MT, Newman SP, Lennard-Jones T et al. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986; 41: 295-300.
18. Pavia D, Lopez-Vidriero MT, Agnew JE, Taylor RG, Eyre-Brook A, Lawton WA et al. Effect of four-week treatment with oxitropium bromide on lung mucociliary clearance in patients with chronic bronchitis or asthma. Respiration 1989; 55: 33-43.
19. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117 (Supl. 2): 63S-6S.
20. Plotnick LH, Ducharme FM. Should inhaled anticholinergics be added to β2 agonists for treating acute childhood and adolescent asthma? A systematic review. Br Med J 1998; 317: 971-7.
21. Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107: 363-70.
22. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159: 156-60.
23. BTS guidelines for the management of chronic obstructive pulmonary disease: the COPD Guideline Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 (Supl. 5): S1-28.
24. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457-64.
25. Takahashi T, Belvisi MG, Patel H, Ward JK, Tadjkarimi S, Yacoub MH, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994; 150: 1640-5.
26. Haddad EB, Mak JC, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994; 45: 899-907.
27. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995; 8: 1506-13.
28. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136-42.
29. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118: 1294-302.
30. Van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289-94.